Series D Startup Financial ModelsPage 2
36 Series D startups with a free, downloadable Excel model - investor-ready 5-year forecasts, valuation, and returns.

Tipalti
$76.0M raisedCloud AP automation platform for mid-market companies - automates end-to-end payables from supplier onboarding through global remittance, tax compliance, and reconciliation.
Roadrunner
$70.0M raisedTech-enabled sustainable waste management and recycling company that replaces legacy haulers for commercial customers.

Front (Series D)
$65.0M raisedFront is a customer communication hub that replaces email and ticketing tools for customer-facing teams, combining inbox UX with real-time collaboration, automation, and analytics.

Iterable
$60.0M raisedCross-channel marketing automation platform for B2C enterprise companies

Squire
$59.0M raisedVertical SaaS + payment processing platform built exclusively for barbershops and men's salons.

Signpost
$52.0M raisedAutomated CRM and marketing platform for local businesses - captures customer data and drives reviews, repeat business, and referrals with zero merchant effort.

Suzy
$34.0M raisedSuzy is an enterprise SaaS market-research platform that delivers consumer insights (surveys, IDIs, focus groups) in minutes via a proprietary opt-in panel.

Signal AI
$25.0M raisedAI-powered "decision augmentation" platform that monitors global media, regulatory, and alternative data sources to surface real-time intelligence for enterprise clients.

Meniga
$16.0M raisedB2B SaaS platform selling data enrichment, personal finance management (PFM), open banking aggregation, and carbon insights to banks and other financial institutions.

Clockworks Analytics
$8.0M raisedB2B SaaS platform providing automated fault-detection and diagnostics (FDD) analytics for commercial and institutional building portfolios.
Bolt
One-click checkout network that lets shoppers transact across any Bolt merchant with a single identity.
Scipher Medicine
AI-powered blood test platform that predicts which autoimmune patients will not respond to biologic therapies, routing them to better drugs from day one.

